Lilly joins cTAP consortium

The Collaborative Trajectory Analysis Project (cTAP) said Eli Lilly has joined the consortium. The group, which includes scientists, drug companies, patient advocacy organizations and clinical centers, is collaborating to advance treatments for Duchenne muscular dystrophy (DMD). cTAP said Lilly will contribute data from its Phase III trial of tadalafil (LY450109) to the collaboration’s natural history database for DMD. cTAP said the data will help researchers understand the variable disease progression prevalent in DMD and may contribute to more effective clinical trial designs. Other cTAP partners include BioMarin Pharmaceutical Inc. (NASDAQ:BMRN, San Rafael, Calif.), Sarepta Therapeutics Inc. (NASDAQ:SRPT, Cambridge, Mass.) and PTC Therapeutics Inc. (NASDAQ:PTCT, South Plainfield, N.J.)...